00338-7/asset/04cdb881-a11b-4ac6-a3c8-ec18b8ddd245/main.assets/gr2_lrg.jpg)
glp 1 nafld Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease GLP-1s Are Just Getting Started:
Description
Patients should not discontinue statins in favour of GLP-1 therapy for cholesterol management without explicit guidance from their healthcare provider, as this could compromise cardiovascular risk reduction
That means researchers were not running a randomized clinical trial where they assign drugs
doi: 10.1093/eurheartj/ehae613
ICC are responsible for multiple functions in the GI tract
To help minimise these effects, starting with a low dose and gradually increasing it under your healthcare provider's guidance can make a difference
